CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    Chou S

    Mutations:

    Mutant Gene Virus Reference
    E22STOP UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    W153R UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    L193F UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    C218del UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    R233S UL27 Human betaherpesvirus 5 Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
    R233S UL27 Human betaherpesvirus 5 Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    A269T UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    301-311del UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    G344D UL27 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V353E UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    W362STOP UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    W362R UL27 Human betaherpesvirus 5 Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. (Jul 2004)
    L426F UL27 Human betaherpesvirus 5 Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. (Jan 2009)
    P91S UL51 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    H142Y UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G143S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    Q229K UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q229K UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E235G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D247N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D262N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A269V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D271A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D284E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D288N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    S290R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    D301N UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D301N UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D301N UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303G UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    E303D UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    A336T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I341T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N345S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G347D UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V355A UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P375L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Y380C UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L394F UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F396L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408H UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N408K UL54 Human betaherpesvirus 5 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Human betaherpesvirus 5 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Human betaherpesvirus 5 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. (Jan 2007)
    N408K UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    N410K UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    N410K UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    N410K UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    F412C UL54 Human betaherpesvirus 5 Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412C UL54 Human betaherpesvirus 5 Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412C UL54 Human betaherpesvirus 5 Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    F412L UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412L UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    F412S UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    D413E UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413E UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413E UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    D413A UL54 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A UL54 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413A UL54 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    D413N UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413N UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413del UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    D413Y UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    L424V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L424V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    K426E UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V450G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F460L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S464F UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    H465Y UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A473V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V476G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V482G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V483A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    N495K UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    P497S UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P497S UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P497S UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    N498S UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    N498S UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L501F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503I UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503I UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503I UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    T503A UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    A505V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A505V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513Q UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    K513R UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    K513R UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D515E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D515Y UL54 Human betaherpesvirus 5 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D515Y UL54 Human betaherpesvirus 5 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D515Y UL54 Human betaherpesvirus 5 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    L516R UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516R UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    L516R UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    I521T UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    I521T UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522T UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    P522L UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    P522A UL54 Human betaherpesvirus 5 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. (Sep 2008)
    C539G UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    C539G UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    D542E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D542E UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A543V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A543V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    L545W UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    L545W UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    T552N UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    L565V UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    L565V UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    L565V UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    Q578H UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578H UL54 Human betaherpesvirus 5 Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. (Apr 2011)
    Q578L UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    Q578L UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    R581H UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D588N UL54 Human betaherpesvirus 5 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    D588N UL54 Human betaherpesvirus 5 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    D588N UL54 Human betaherpesvirus 5 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    C590F UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D594N UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D594N UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D594N UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    P617S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A626V UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P628L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P628A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A631G UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V634A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M640R UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S651E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G653S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V654G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S655L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S660G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S660N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S663N UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G667N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G667N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F669L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S676G UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G678S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N685S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A688V UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T691A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T691S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A692S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A693T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    Q697H UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V715M UL54 Human betaherpesvirus 5 Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    V715M UL54 Human betaherpesvirus 5 Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    V715M UL54 Human betaherpesvirus 5 Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. (Mar 1996)
    F718L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    F718S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    I726V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E756D UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756D UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756D UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756K UL54 Human betaherpesvirus 5 Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. (Jul 2003)
    E756Q UL54 Human betaherpesvirus 5 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E756Q UL54 Human betaherpesvirus 5 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E756Q UL54 Human betaherpesvirus 5 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    L773V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L773V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    L776M UL54 Human betaherpesvirus 5 Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    L776M UL54 Human betaherpesvirus 5 Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    L776M UL54 Human betaherpesvirus 5 Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. (May 2008)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    Q783R UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A786V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A786V UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    V787L UL54 Human betaherpesvirus 5 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V787L UL54 Human betaherpesvirus 5 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    V787L UL54 Human betaherpesvirus 5 Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. (Mar 2003)
    E793V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E793V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795P UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q795R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V798A UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    R800C UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    L802M UL54 Human betaherpesvirus 5 Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802M UL54 Human betaherpesvirus 5 Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    L802M UL54 Human betaherpesvirus 5 Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. (Sep 1997)
    A809V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Human betaherpesvirus 5 Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. (Aug 2014)
    A809V UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A809V UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V812L UL54 Human betaherpesvirus 5 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. (Jun 2016)
    T813S UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    T813S UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G822D UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V823A UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V823A UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    V823A UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    M827I UL54 Human betaherpesvirus 5 Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I UL54 Human betaherpesvirus 5 Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I UL54 Human betaherpesvirus 5 Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M827I UL54 Human betaherpesvirus 5 Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis. (Jul 2016)
    M828V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T838A UL54 Human betaherpesvirus 5 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    T838A UL54 Human betaherpesvirus 5 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    T838A UL54 Human betaherpesvirus 5 How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. (Jan 2005)
    G841S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G841A UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    G841A UL54 Human betaherpesvirus 5 Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. (Nov 2007)
    M844T UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844T UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    M844V UL54 Human betaherpesvirus 5 Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. (Jan 2012)
    R847H UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    N855D UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    P859A UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    H863R UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    Q868R UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D870H UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V873L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G874R UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in884T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A885T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    in885T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P887S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L890S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L890F UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    T892I UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    S897L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N898D UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    E899K UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    V902G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V902G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E903G UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    G920S UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    V927M UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A928T UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    A928T UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    K947E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    K947E UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    E949K UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949K UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E949Q UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E951D UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    V953A UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    M959T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    M959T UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A972V UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    981-982del UL54 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    D981del UL54 Human betaherpesvirus 5 A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    D981del UL54 Human betaherpesvirus 5 A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    D981del UL54 Human betaherpesvirus 5 A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. (Dec 2000)
    A987V UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987V UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987V UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    A987G UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A987G UL54 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    E989D UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989D UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    E989D UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    S1000L UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    D1005N UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    R1006C UL54 Human betaherpesvirus 5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial. (Apr 2014)
    A1012V UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1020I UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    T1108A UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1116H UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    A1122T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G1133S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1146N UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    N1147S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    R1149T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    G1151del UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    P1153S UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    L1156del UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1162L UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    S1235T UL54 Human betaherpesvirus 5 Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. (Jun 1999)
    D981del2 UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 UL54 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    D981del2 UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Human betaherpesvirus 5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    D981del2 UL54 Human betaherpesvirus 5 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 UL54 Human betaherpesvirus 5 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    D981del2 UL54 Human betaherpesvirus 5 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    C25F UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    S229F UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    S229Y UL56 Human betaherpesvirus 5 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    V231A UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V231L UL56 Human betaherpesvirus 5 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    V231L UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    N232Y UL56 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    Q234R UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V236A UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V236L UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V236M UL56 Human betaherpesvirus 5 Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    E237D UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L243P UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    T244K UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L254F UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257F UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257I UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    K258E UL56 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    F261C UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    F261L UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    S262C UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    Y321C UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325W UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    C325F UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325R UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L328V UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    L328I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    M329T UL56 Human betaherpesvirus 5 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    M329I UL56 Human betaherpesvirus 5 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    H335Y UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    E339G UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    K350R UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V363I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    A365S UL56 Human betaherpesvirus 5 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    N368D UL56 Human betaherpesvirus 5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    N368I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    R369T UL56 Human betaherpesvirus 5 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020)
    R369K UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    T399I UL56 Human betaherpesvirus 5 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    N320H UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    N329S UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    D344E UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    D344E UL89 Human betaherpesvirus 5 Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    T350M UL89 Human betaherpesvirus 5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    M359I UL89 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    Q19E UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    N68D UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    S108N UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    S108N UL97 Human betaherpesvirus 5 Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    L126Q UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    G215A UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    I244V UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    P247S UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    D329H UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    Y335H UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    Y335H UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L337M UL97 Human betaherpesvirus 5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    L337M UL97 Human betaherpesvirus 5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    F342S UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342S UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    F342Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    G343A UL97 Human betaherpesvirus 5 Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (Sep 2024)
    G343A UL97 Human betaherpesvirus 5 Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. (Sep 2024)
    V345I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V345I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L348V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L348V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V353A UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
    V353A UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
    K355del UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K355del UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K359E UL97 Human betaherpesvirus 5 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    K359Q UL97 Human betaherpesvirus 5 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    E362D UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    E362D UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V388M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    V388M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    L397R UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L397R UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L405P UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    T409M UL97 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    T409M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    T409M UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y UL97 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    H411Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411L UL97 Human betaherpesvirus 5 Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411L UL97 Human betaherpesvirus 5 Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411N UL97 Human betaherpesvirus 5 Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411N UL97 Human betaherpesvirus 5 Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H415Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    H415Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A435V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A435V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    C437Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    C437Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing. (Sep 2021)
    A440V UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. (Dec 2010)
    A442G UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. (Dec 2010)
    Q449K UL97 Human betaherpesvirus 5 Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    Q449K UL97 Human betaherpesvirus 5 Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    D456N UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    D456N UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    M460I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460I UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460T UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    M460I UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    M460V UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    V466G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V466M UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    H469Y UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    A478V UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    C480F UL97 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    C480F UL97 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    C480F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480R UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    C480R UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    N510S UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    H520Q UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H520Q UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H520Q UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    P521L UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    P521L UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    G561A UL97 Human betaherpesvirus 5 Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    H587Y UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    A588V UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    591-607del UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    C592G UL97 Human betaherpesvirus 5 Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    C592G UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C592G UL97 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    C592G UL97 Human betaherpesvirus 5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene. (Feb 2017)
    A594E UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    A594P UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594P UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594V UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594S UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594V UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594T UL97 Human betaherpesvirus 5 Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    A594T UL97 Human betaherpesvirus 5 Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    L595F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595F UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    595-603del UL97 Human betaherpesvirus 5 Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. (Mar 1999)
    E596Q UL97 Human betaherpesvirus 5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    E596G UL97 Human betaherpesvirus 5 Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    N597del UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-598del UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-599del UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    K599R UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L600I UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    601-602del UL97 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    601-603del UL97 Human betaherpesvirus 5 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    T601M UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C603W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603W UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y UL97 Human betaherpesvirus 5 Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603W UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    D605E UL97 Human betaherpesvirus 5 Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    Y617del UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    Y617del UL97 Human betaherpesvirus 5 Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    T659I UL97 Human betaherpesvirus 5 Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230